Related Experiment Video
Updated: Oct 9, 2026

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
Published on: February 17, 2018
PET in Cardiac Sarcoidosis
Chetan D Patel1, Aman Tilak1, Chakshine Shiva1
1Department of Nuclear Medicine, All India Institute of Medical Sciences, Ansari Nagar East, New Delhi, Delhi 110029, India.
Abstract:
18F-fluorodeoxyglucose (18F-FDG) PET is used to diagnose cardiac sarcoidosis (CS) in patients with extracardiac sarcoidosis and suspected cardiac involvement or suspected isolated CS. Rigorous patient preparation suppresses physiological myocardial uptake. 18F-FDG PET is interpreted with myocardial perfusion imaging: abnormal uptake with normal perfusion indicates inflammation without fibrosis, uptake with a perfusion defect indicates inflammation with fibrosis, and a perfusion defect without uptake indicates fibrosis alone. Abnormal uptake, particularly with perfusion defects, predicts major adverse cardiac events, including death and ventricular arrhythmias. Serial 18F-FDG PET monitors response to immunosuppressive therapy and detects reactivation of myocardial inflammation.
Related Concept Videos
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Pericarditis II: Clinical Features and Diagnostic Tests
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy II: Dilated Cardiomyopathy
Myocarditis II: Clinical Features and Diagnostic Tests
